{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:16:16Z","timestamp":1789683376919,"version":"4.0.1"},"reference-count":58,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Lysophosphatidylcholine (LPC) is composed of various lipid species, some of which exert pro-inflammatory and others anti-inflammatory activities. However, most of the LPC species analyzed to date are reduced in the serum of patients with inflammatory bowel disease (IBD) compared to healthy controls. To our knowledge, the correlation between serum LPC species levels and measures of inflammation, as well as their potential as markers for monitoring IBD activity, has not yet been investigated. Methods: Thirteen LPC species, varying in acyl chain length and number of double bonds, were measured in the serum of 16 controls and the serum of 57 patients with IBD. Associations with C-reactive protein (CRP) and fecal calprotectin levels as markers of IBD severity were assessed. Results: Serum levels of LPC species did not differ between the healthy controls and the entire patient cohort. In patients with IBD, serum levels of LPC 16:1, 18:0, 18:3, 20:3, and 20:5, as well as total LPC concentrations, showed inverse correlations with both CRP and fecal calprotectin levels, indicating an association with inflammatory activity. Nine LPC species were significantly reduced in patients with high fecal calprotectin compared to those with low values. LPC species with 22 carbon atoms and 4 to 6 double bonds were not related to disease activity. Stool consistency and gastrointestinal symptoms did not influence serum LPC profiles. Corticosteroid treatment was associated with lower serum LPC 20:3 and 22:5 levels, while mesalazine, anti-TNF, and anti-IL-12\/23 therapies had no significant impact on LPC concentrations. There was a strong positive correlation between LPC species containing 15 to 18 carbon atoms and serum cholesterol, triglycerides, and phosphatidylcholine levels. However, there was no correlation with markers of liver disease. Conclusions: Shorter-chain LPC species are reduced in patients with active IBD and reflect underlying hypolipidemia. While these lipid alterations provide insight into IBD-associated metabolic changes, they appear unsuitable as diagnostic or disease monitoring biomarkers.<\/jats:p>","DOI":"10.3390\/jcm14155485","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T08:46:55Z","timestamp":1754383615000},"page":"5485","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Decline in Serum Lysophosphatidylcholine Species in Patients with Severe Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"14","author":[{"given":"Hauke Christian","family":"Tews","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Elger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Huss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Loibl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9065-8395","authenticated-orcid":false,"given":"Arne","family":"Kandulski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"H\u00f6ring","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4886-0811","authenticated-orcid":false,"given":"Gerhard","family":"Liebisch","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-3994","authenticated-orcid":false,"given":"Christa","family":"Buechler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"ref_1","unstructured":"Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., and Hofland, J. (2000). The Effect of Inflammation and Infection on Lipids and Lipoproteins. Endotext, Endotext."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1194\/jlr.D800028-JLR200","article-title":"Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry","volume":"50","author":"Wiesner","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12944-019-0977-8","article-title":"Changes in lipids composition and metabolism in colorectal cancer: A review","volume":"18","author":"Pakiet","year":"2019","journal-title":"Lipids Health Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4062\/biomolther.2021.125","article-title":"Systematic Review of Recent Lipidomics Approaches Toward Inflammatory Bowel Disease","volume":"29","author":"Lee","year":"2021","journal-title":"Biomol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bauset, C., Gisbert-Ferrandiz, L., and Cosin-Roger, J. (2021). Metabolomics as a Promising Resource Identifying Potential Biomarkers for Inflammatory Bowel Disease. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040622"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_7","first-page":"181","article-title":"An overview of lipid abnormalities in patients with inflammatory bowel disease","volume":"24","author":"Agouridis","year":"2011","journal-title":"Ann. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Alhouayek, M., Ameraoui, H., and Muccioli, G.G. (2021). Bioactive lipids in inflammatory bowel diseases\u2014From pathophysiological alterations to therapeutic opportunities. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1866.","DOI":"10.1016\/j.bbalip.2020.158854"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Chen, H., Li, W., Hu, J., Xu, F., Lu, Y., Zhu, L., and Shen, H. (2023). Association of serum lipids with inflammatory bowel disease: A systematic review and meta-analysis. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1198988"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jacl.2010.08.021","article-title":"Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease","volume":"4","author":"Putka","year":"2010","journal-title":"J. Clin. Lipidol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yan, D., Ye, S., He, Y., Wang, S., Xiao, Y., Xiang, X., Deng, M., Luo, W., Chen, X., and Wang, X. (2023). Fatty acids and lipid mediators in inflammatory bowel disease: From mechanism to treatment. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1286667"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: Current state of the art","volume":"13","author":"Fiocchi","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.disamonth.2017.07.001","article-title":"A comprehensive review and update on Crohn\u2019s disease","volume":"64","author":"Gajendran","year":"2018","journal-title":"Dis. Mon."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/apt.16703","article-title":"Systematic review with meta-analysis: Environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations","volume":"55","author":"Zhao","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41575-025-01038-y","article-title":"Influence of biological sex in inflammatory bowel diseases","volume":"22","author":"Tshikudi","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"106177","DOI":"10.18632\/oncotarget.22425","article-title":"Lysophosphatidylcholine induces cytotoxicity\/apoptosis and IL-8 production of human endothelial cells: Related mechanisms","volume":"8","author":"Chang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"117443","DOI":"10.1016\/j.lfs.2020.117443","article-title":"The mechanisms of lysophosphatidylcholine in the development of diseases","volume":"247","author":"Liu","year":"2020","journal-title":"Life Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1073\/pnas.91.3.1069","article-title":"Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes","volume":"91","author":"Nakano","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1194\/jlr.M200401-JLR200","article-title":"Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients","volume":"44","author":"Drobnik","year":"2003","journal-title":"J Lipid Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11306-018-1439-4","article-title":"Italian cohort of patients affected by inflammatory bowel disease is characterised by variation in glycerophospholipid, free fatty acids and amino acid levels","volume":"14","author":"Murgia","year":"2018","journal-title":"Metabolomics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acs.jproteome.9b00440","article-title":"UPLC-QTOF-MS-Based Plasma Lipidomic Profiling Reveals Biomarkers for Inflammatory Bowel Disease Diagnosis","volume":"19","author":"Guan","year":"2020","journal-title":"J. Proteome Res."},{"key":"ref_22","first-page":"262","article-title":"The potential of metabolic and lipid profiling in inflammatory bowel diseases: A pilot study","volume":"20","author":"Tefas","year":"2020","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ibd\/izy402","article-title":"Untargeted Metabolomics and Inflammatory Markers Profiling in Children With Crohn\u2019s Disease and Ulcerative Colitis-A Preliminary Study","volume":"25","author":"Daniluk","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1388-1981(00)00153-0","article-title":"Lecithin cholesterol acyltransferase","volume":"1529","author":"Jonas","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.intimp.2005.01.003","article-title":"A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis","volume":"5","author":"Woodruff","year":"2005","journal-title":"Int. Immunopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/S0006-2952(97)00137-8","article-title":"Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: A novel mechanism of anti-inflammatory activity","volume":"53","author":"Pruzanski","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3399\/bjgp18X699341","article-title":"Using corticosteroids appropriately in inflammatory bowel disease: A guide for primary care","volume":"68","author":"Barrett","year":"2018","journal-title":"Br. J. Gen. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12745","DOI":"10.1016\/S0021-9258(19)38408-X","article-title":"Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression","volume":"265","author":"Nakano","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0162-3109(88)90041-0","article-title":"A comparison of effects of sulfasalazine and its metabolites on the metabolism of endogenous vs. exogenous arachidonic acid","volume":"15","author":"Allgayer","year":"1988","journal-title":"Immunopharmacology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/003655298750026813","article-title":"Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn\u2019s disease. Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn\u2019s disease","volume":"33","author":"Wolbink","year":"1998","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00508-009-1150-6","article-title":"Cholesterol metabolism in active Crohn\u2019s disease","volume":"121","author":"Hrabovsky","year":"2009","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/gut.2005.069476","article-title":"Laboratory markers in IBD: Useful, magic, or unnecessary toys?","volume":"55","author":"Vermeire","year":"2006","journal-title":"Gut"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2036.2008.03886.x","article-title":"Plasma lipids and inflammation in active inflammatory bowel diseases","volume":"29","author":"Romanato","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000527846","article-title":"Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease","volume":"104","author":"Sakurai","year":"2023","journal-title":"Digestion"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4292\/wjgpt.v8.i1.39","article-title":"Update on clinical and research application of fecal biomarkers for gastrointestinal diseases","volume":"8","author":"Siddiqui","year":"2017","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1053\/j.gastro.2015.07.003","article-title":"Biomarkers of Inflammation in Inflammatory Bowel Disease","volume":"149","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects","volume":"13","author":"Sturm","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_38","first-page":"29","article-title":"Quantification of lysophosphatidylcholine species by high-throughput electrospray ionization tandem mass spectrometry (ESI-MS\/MS)","volume":"580","author":"Liebisch","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1139\/y59-099","article-title":"A rapid method of total lipid extraction and purification","volume":"37","author":"Bligh","year":"1959","journal-title":"Can. J. Biochem. Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbalip.2004.09.003","article-title":"High-throughput quantification of phosphatidylcholine and sphingomyelin by electrospray ionization tandem mass spectrometry coupled with isotope correction algorithm","volume":"1686","author":"Liebisch","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1021\/acs.analchem.8b05013","article-title":"Quantification of Cholesterol and Cholesteryl Ester by Direct Flow Injection High-Resolution Fourier Transform Mass Spectrometry Utilizing Species-Specific Response Factors","volume":"91","author":"Horing","year":"2019","journal-title":"Anal. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Weigand, K., Peschel, G., Grimm, J., Horing, M., Krautbauer, S., Liebisch, G., Muller, M., and Buechler, C. (2024). Serum Phosphatidylcholine Species 32:0 as a Biomarker for Liver Cirrhosis Pre- and Post-Hepatitis C Virus Clearance. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158161"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100050","DOI":"10.1016\/j.jlr.2021.100050","article-title":"Accurate quantification of lipid species affected by isobaric overlap in Fourier-Transform mass spectrometry","volume":"62","author":"Horing","year":"2021","journal-title":"J. Lipid Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4097\/kjae.2016.69.1.8","article-title":"Nonparametric statistical tests for the continuous data: The basic concept and the practical use","volume":"69","author":"Nahm","year":"2016","journal-title":"Korean J. Anesthesiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1002\/elps.201200629","article-title":"Serum lipid profiling of patients with chronic hepatitis B, cirrhosis, and hepatocellular carcinoma by ultra fast LC\/IT-TOF MS","volume":"34","author":"Chen","year":"2013","journal-title":"Electrophoresis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.metabol.2006.03.006","article-title":"Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: Consequences on the cholesterol efflux capacity of serum using Fu5AH cell system","volume":"55","author":"Nazih","year":"2006","journal-title":"Metabolism"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Law, S.H., Chan, M.L., Marathe, G.K., Parveen, F., Chen, C.H., and Ke, L.Y. (2019). An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051149"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bazarganipour, S., Hausmann, J., Oertel, S., El-Hindi, K., Brachtendorf, S., Blumenstein, I., Kubesch, A., Sprinzl, K., Birod, K., and Hahnefeld, L. (2019). The Lipid Status in Patients with Ulcerative Colitis: Sphingolipids are Disease-Dependent Regulated. J. Clin. Med., 8.","DOI":"10.3390\/jcm8070971"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1194\/jlr.R036095","article-title":"Unraveling the complexities of the HDL lipidome","volume":"54","author":"Kontush","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/jgh.16895","article-title":"Review Article: Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future","volume":"40","author":"Cameron","year":"2025","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1111\/liv.14580","article-title":"Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV\/HCV-coinfected and HCV-monoinfected patients","volume":"40","author":"Salguero","year":"2020","journal-title":"Liver Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/apt.16580","article-title":"Systematic review with meta-analysis: Effect of inflammatory bowel disease therapy on lipid levels","volume":"54","author":"Sleutjes","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/gut.33.7.914","article-title":"Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: Its correlation with disease activity of Crohn\u2019s disease and ulcerative colitis","volume":"33","author":"Minami","year":"1992","journal-title":"Gut"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Jiang, J.J., Chen, L., Sun, R., Yu, T., Jiang, S.Y., and Chen, H. (2023). Characterization of serum polyunsaturated fatty acid profile in patients with inflammatory bowel disease. Ther. Adv. Chronic Dis., 14.","DOI":"10.1177\/20406223231156826"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"111448","DOI":"10.1016\/j.mce.2021.111448","article-title":"The role of fatty acids in Crohn\u2019s disease pathophysiology\u2014An overview","volume":"538","author":"Piotrowska","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"39436","DOI":"10.1074\/jbc.M205623200","article-title":"Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase","volume":"277","author":"Tokumura","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/labinvest.2013.45","article-title":"Involvement of autotaxin\/lysophospholipase D expression in intestinal vessels in aggravation of intestinal damage through lymphocyte migration","volume":"93","author":"Hozumi","year":"2013","journal-title":"Lab. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10787-016-0284-1","article-title":"Differences between serum polar lipid profiles of male and female rheumatoid arthritis patients in response to glucocorticoid treatment","volume":"24","author":"Fu","year":"2016","journal-title":"Inflammopharmacology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5485\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:22:50Z","timestamp":1760034170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":58,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14155485"],"URL":"https:\/\/doi.org\/10.3390\/jcm14155485","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}